AstraZeneca beat expectations for third quarter earnings on Thursday with strong sales of its blockbuster cancer and ...

AstraZeneca beat third-quarter earnings expectations on Thursday, helped by strong sales of its cancer, heart and kidney ...

Fueled by gains in all of its therapeutic areas, the company had a triumphant third quarter.

On Friday, AstraZeneca ADR AZN reached a noteworthy performance benchmark, seeing its Relative Strength (RS) Rating jump into ...

AstraZeneca has ended work on one of its potential drugs for fatty liver disease after viewing disappointing data from a ...

CEO warns continent’s advantage in the industry could fade as companies build new high-tech factories elsewhere ...

The “most favored nation” (MFN) drug pricing deal AstraZeneca recently signed with the Trump administration won’t affect the ...

In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based ...

NHS patients risk losing access to the world’s best medicines unless the UK spends more on developing new treatments, the ...

AstraZeneca said work on its new plant north of Charlottesville will begin immediately and be open within five years.

AstraZeneca has paused global trials of its experimental coronavirus vaccine after an unexplained illness in a participant, ...

The pharmaceutical company posted a 14% on-year increase in third-quarter core earnings per share, while revenue rose to ...